Takeda agreed to pay $13.67 million to settle allegations that it caused false claims submissions to Medicare and other federal programs by paying kickbacks to induce prescriptions of its antidepressant Trintellix. The Department of Justice pursued the case under the False Claims Act, focusing on illegal kickbacks to healthcare providers.
Latest development
Media Coverage · May 14, 2026
Takeda Pharmaceuticals agreed to pay $13.67 million to settle claims that it paid kickbacks to doctors to induce prescriptions of its antidepressant, Trintellix. The payments allegedly caused false claims to be submitted to Medicare and other federal health programs. This settlement ends the government's investigation into Takeda's marketing practices for this drug.
newspaper Read articleCourt
Court not identified
Awaiting court metadata
Docket
Not captured
Civil
Stage
Active litigation
Active
Filed
Date unavailable
Not in the available feed
Latest Filing
Takeda Pharmaceuticals Agrees to Pay $13.6 Million to Resolve False Claims Allegations Relating to Improper Payments to
Media Coverage · May 14, 2026
Coverage
2 articles
1 source tracked
Participants
7 Government Agencys
9 linked entities
Judge
Not assigned in feed
The court metadata has not been resolved yet, so Juryvine is keeping the page conservative until a reliable court match lands.
The newest docket activity we have is a media coverage dated May 14, 2026.
The visible party/entity graph currently includes Department of Justice, A Department and others.
Press monitoring has found 2 related articles from 1 distinct source.
Takeda Pharmaceuticals, U.S.A., Inc. has agreed to pay $13,670,921 to resolve allegations that it knowingly caused the submission of false claims to Medicare and other federal health care programs by paying kickbacks to healthcare providers to induce prescriptions of Trintellix, an antidepressant medication that Takeda marketed and sold to treat major depressive disorder.
Open original open_in_newhas agreed to pay $13,670,921 to resolve allegations that it knowingly caused the submission of false claims to Medicare and other federal health care programs by paying kickbacks to healthcare providers to induce prescriptions of Trintellix, an antidepressant medication that Takeda marketed and sold to treat major depressive disorder. “The Department of Justice is committed to vigorously pursuing violations of the False Claims Act arising from illegal kickbacks,” said Assistant Attorney General
Open original open_in_newJuryvine summaries are generated from court records. Expand "Source" on any row to see the underlying filing.
Takeda Pharmaceuticals agreed to pay $13.67 million to settle claims that it paid kickbacks to doctors to induce prescriptions of its antidepressant, Trintellix. The payments allegedly caused false claims to be submitted to Medicare and other federal health programs. This settlement ends the government's investigation into Takeda's marketing practices for this drug.
The parties reported a settlement.
Takeda Pharmaceuticals, U.S.A., Inc. has agreed to pay $13,670,921 to resolve allegations that it knowingly caused the submission of false claims to Medicare and other federal health care programs by …
has agreed to pay $13,670,921 to resolve allegations that it knowingly caused the submission of false claims to Medicare and other federal health care programs by paying kickbacks to healthcare …
Sources tracked
1 outlet · 2 articles
Timeline events
2 records on file
Last updated
9 hours, 52 minutes ago
Juryvine aggregates docket entries from PACER/CourtListener, press coverage, and GDELT signals. Ingestion timestamps do not appear in the What Changed feed — that reflects real court activity only.